Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Infections × Lenalidomide × Clear all

Phase

Status

Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 6 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma, Follicular 3 Lymphoma, B-Cell, Marginal Zone 2 Triple Negative Breast Neoplasms 1 Lymphoma, Mantle-Cell 1 Lymphoma 1 Infections 1 Epstein-Barr Virus Infections 1

Interventions

Tenofovir 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1 Lenalidomide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07133776 2025-08-21

Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.

The Affiliated Hospital of Xuzhou Medical University

Phase 1/2 Not yet recruiting

Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡